FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Barnes Alane P</u>			<u>B</u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
			(1.0.)	- 5	BCKA J) J	Officer (below)	(give title	Other (s below)	pecify	
(Last) (First) (Middle) 4505 EMPEROR BLVD.				3. Date of Earliest Transaction (Month/Day/Year)						VP, Ge	General Counsel & Corp Sec				
SUITE 200			U	05/23/2016											
				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) DURHA	M N	C	27703								<u>></u>		ed by One Rep	orting Persor	
			27703									Form fil Person	ed by More tha	One Repor	ing
(City)	(S	itate)	(Zip)									1 013011			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			te	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr 8)	Disposed	Securities Acquired (A) sposed Of (D) (Instr. 3, 4 nount (A) or (D)		5. Amoun Securities Beneficia Owned For Reported Transacti (Instr. 3 a	s Forn lly (D) c ollowing (I) (II on(s)	n: Direct or Indirect ostr. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) if any Code (Instr. Securities e of (Month/Day/Year) (Month/Day/Year) 8) Acquired (or Dispose		(A) ed	Expiration Date (Month/Day/Year) of Securities Underlying Derivative Sec (Instr. 3 and 4			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Emp. Stock Option (Right to Buy)	\$3.22	05/23/2016		A		91,004 ⁽¹⁾		05/23/2017	05/23/2026	Common Stock	91,004	\$0	91,004	D	

Explanation of Responses:

1. Retention Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes

05/25/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.